(Q42665272)

4 November 2017

Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. (English)

1 reference

4 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

Teresa L Kauf

1

1 reference

4 November 2017

Raymond A Farkouh

2

1 reference

4 November 2017

Stephanie R Earnshaw

3

1 reference

4 November 2017

Maria E Watson

4

1 reference

4 November 2017

Penny Maroudas

5

1 reference

4 November 2017

Mike G Chambers

6

1 reference

4 November 2017

1 January 2010

1 reference

4 November 2017

1 reference

4 November 2017

28

1 reference

4 November 2017

11

1 reference

4 November 2017

1025-1039

1 reference

https://scigraph.springernature.com/pub.10.2165/11535540-000000000-00000

4 November 2017

0 references

cites work

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

1 reference

12 December 2020

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

1 reference

12 December 2020

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

1 reference

12 December 2020

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

1 reference

12 December 2020

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

1 reference

12 December 2020

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

1 reference

12 December 2020

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

1 reference

12 December 2020

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

The abacavir hypersensitivity reaction: a review

1 reference

12 December 2020

An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses.

1 reference

12 December 2020

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

12 December 2020

HLA-B*5701 screening for hypersensitivity to abacavir

1 reference

12 December 2020

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

1 reference

12 December 2020

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

12 December 2020

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

1 reference

12 December 2020

Identification of abacavir hypersensitivity reaction in health care claims data

1 reference

12 December 2020

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

12 December 2020

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

12 December 2020

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

1 reference

12 December 2020

A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy.

1 reference

12 December 2020

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

12 December 2020

10.2165/11535540-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

4 November 2017

0 references

1 reference